NCT00605761View on ClinicalTrials.gov

SD Cystic Fibrosis Study

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Cystic Fibrosis
Interventions
DRUG

SB656933

50 mg treatment

DRUG

SB656933

150 mg treatment

Trial Locations (3)

15213

GSK Investigational Site, Pittsburgh

55455

GSK Investigational Site, Minneapolis

94304

GSK Investigational Site, Palo Alto

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00605761 - SD Cystic Fibrosis Study | Biotech Hunter | Biotech Hunter